Aurobindo Pharma Ltd · NSE:AUROPHARMA
Aurobindo Pharma — Q4 FY2018 Earnings Presentation
9 slides from Aurobindo Pharma's earnings presentation, May 28, 2018
Slide 1: Q4 FY17-18 Earnings Presentation
Q4 FY17-18 EARNINGS PRESENTATION 28th May 2018
Slide 2: Disclaimer
Disclaimer This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these
Slide 3: Consolidated Financial – Q4FY18 & FY18
Consolidated Financial – Q4FY18 & FY18 Key Financial Highlights Q4FY18 Performance • Revenue from operations at INR 4,049.1 crore, an increase of 11.2% YoY • EBIDTA before forex and other income at INR 804.0 crore, up by 11.5% YoY; EBITDA margin is at 19.9% • Net Profit after JV share, minority inte
Slide 4: Business Highlights – Q4FY18 & FY18
Business Highlights – Q4FY18 & FY18 Key Business Highlights US Formulations • In FY18, US revenue increased by INR 7,442.1 crore compared to INR 6,827.2 crore in FY17, accounting for 45% of consolidated revenue. On constant currency basis, revenue grew by 13.4% to US$ 1,156 million • US revenue for
Slide 5: US Filings Snapshot
US Filings Snapshot Addressable Cumulative ANDA Filings and Approvals Therapy ANDAs Market Size (US$ Bn) Anti Diabetic 15 6.3 ARV** 42 7.0 CNS 90 24.6 Controlled Substances 16 1.7 CVS 76 24.5 Gastroenterological 30 4.1 Ophthalmics 11 0.5 Others 142 15.5 Penem 2 0.5 Respiratory 11 0.7 Oncology & Horm
Slide 6: Consolidated Financial Performance – Q4FY18
Consolidated Financial Performance – Q4FY18 Q4 Q4 % Value INR Cr Revenue from Operations - Breakup FY18 FY17 Chg Value in INR Cr Q4FY18 Q4FY17 % Chg Formulations 3,248.6 2,879.4 12.8 USA 1,738.8 1,643.2 5.8% API 799.6 762.8 4.8 EU 1,151.6 777.2 48.2% Formulations % of sales 80.2% 79.1% Growth market
Slide 7: Consolidated Financial Performance – FY18
Consolidated Financial Performance –FY18 % Revenue from operations - Breakup Value INR Cr FY18 FY17 Chg Value in INR Cr FY18 FY17 % Chg Formulations 13,533.2 12,045.4 12.4 USA 7,442.1 6,827.2 9.0% API 2,962.2 3,042.1 -2.6 EU 4,354.4 3,277.1 32.9% Growth markets 897.1 755.6 18.7% Formulations % of sa
Slide 8: Debt Profile
Debt Profile Fx Loan US$ Mn Debt as on (INR Cr) Mar-16 Mar-17 Dec-17 Mar-18 Closing Rate1 US$ = 66.25 64.85 63.875 65.175 INR Fx Loan restated in 4,956.7 3,121.5 4,608.8 4,766.9 748 481 722 731 INR Rupee Loan 46.9 244.8 92.9 4.1 Sales Tax Deferment 41.9 0.0 0.0 0.0 Gross Debt 5,045.6 3,366.3 4,701.7
Slide 9: Thank You
Thank You For updates and specific queries, please visit our website www. aurobindo.com Investor Relations: Phone: +91-40-66725000/5401 +91 98486 67906 Email: [email protected] Corporate Office: Water Mark Building, Level-1, Plot No.11, Survey No. 9, Kondapur, Hitech City, Hyderabad - 500084 Register